Thursday, July 27, 2017 8:31:49 AM
_______________________________________________________________
AstraZeneca shares plummet 16% on late-stage trial failure; Bristol-Myers shares fall 6% and Merck shares rise 5%
Published: July 27, 2017 8:07 a.m. ET
AstraZeneca PLC AZN, -15.35% shares plummeted as much as 16% in premarket trade Thursday after the company said its cancer drug combination failed to meet its primary endpoint in a late-stage clinical trial. In the AstraZeneca late-stage trial, the combination of the drugs Imfinzi and tremelimumab -- intended for previously-untreated patients with metastatic first-line non-small cell lung cancer -- did not improve progression-free survival compared to the standard of care. The results could have implications for Bristol-Myers Squibb Co.'s BMY, -5.06% cancer drug combination, and the company's shares dropped 6.2% in premarket trade. Meanwhile, shares of cancer drug rival Merck & Co. MRK, +5.08% -- which has a key position in the first-line lung cancer market with cancer drug Keytruda -- rose 5% in premarket trade. For AstraZeneca, "this is a clear disappointment given the large market opportunity," said Leerink Research analyst Seamus Fernandez. "The read-through is an obvious negative read-through for BMY's combo of Opdivo and Yervoy in the ongoing CheckMate-227 trial... While there are several key differences in trial design between MYSTIC and CM-227, they are unlikely to result in meaningfully different outcomes." However, EvercoreISI analyst Umer Raffat was slightly more optimistic, noting that the AstraZeneca trial isn't over yet and also has overall survival as a primary endpoint, with results expected in the first half of next year. "It will be unreasonable to pretend as if nothing has changed on MYSTIC... but I also acknowledge that we shouldn't forget about several [immuno-oncology] trials which have delivered [overall survival] benefit despite not having any [progression-free survival] benefit," Raffat said. AstraZeneca shares have surged 10% over the last three months, Bristol-Myers shares have lifted 0.6% and Merck shares have dropped 1.3%, compared with a 3.7% rise in the S&P 500 SPX, +0.03%
______________________________________________
http://www.marketwatch.com/story/astrazeneca-shares-plummet-16-on-late-stage-trial-failure-bristol-myers-shares-fall-6-and-merck-shares-rise-5-2017-07-27
BMY
Recent BMY News
- Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung… • Business Wire • 03/28/2024 08:05:00 PM
- Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn’s Disease • Business Wire • 03/28/2024 08:01:00 PM
- Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results • GlobeNewswire Inc. • 03/28/2024 11:30:08 AM
- A Bristol Myers Squibb Expande as Iniciativas de Doações para a Equidade em Saúde a fim de Melhorar os Resultados de Saúde • Business Wire • 03/26/2024 06:25:00 PM
- Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes • Business Wire • 03/26/2024 10:59:00 AM
- Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascular Portfolio • Business Wire • 03/25/2024 12:00:00 PM
- Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma • Business Wire • 03/20/2024 08:45:00 PM
- Bristol Myers Squibb Announces CheckMate -9DW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Meets Primary Endpoint of Overall Survival for the First-Line Treatment of Advanced Hepatocellular Carcinoma • Business Wire • 03/20/2024 10:59:00 AM
- Bristol Myers Squibb and Ted Danson Empower Those with Plaque Psoriasis to Take Action in “SO, Have You Found It?” Campaign • Business Wire • 03/19/2024 10:59:00 AM
- Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio • Business Wire • 03/18/2024 12:44:00 PM
- FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy • Business Wire • 03/15/2024 10:27:00 PM
- U.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) • Business Wire • 03/15/2024 01:35:00 AM
- Bristol Myers Squibb to Report Results for First Quarter 2024 on April 25, 2024 • Business Wire • 03/11/2024 08:16:00 PM
- U.S. Food and Drug Administration Approves Opdivo® (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma • Business Wire • 03/07/2024 07:23:00 PM
- Bristol Myers Squibb to Participate in Upcoming Investor Conferences • Business Wire • 03/06/2024 09:17:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 10:57:57 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 10:52:54 PM
- Bristol Myers Squibb Announces Dividend • Business Wire • 03/01/2024 09:16:00 PM
- Bristol Myers Squibb Announces New Data from the Long-Term DAYBREAK Study Reinforcing Efficacy and Safety of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis • Business Wire • 02/29/2024 11:59:00 AM
- Bristol Myers Squibb to Participate in the TD Cowen 44th Annual Health Care Conference • Business Wire • 02/26/2024 09:16:00 PM
- Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform • Business Wire • 02/26/2024 01:35:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 11:03:45 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 02/23/2024 12:34:04 PM
- Bristol Myers Squibb Announces Expiration of RayzeBio Tender Offer • Business Wire • 02/23/2024 11:59:00 AM
- Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Treatment of Adults with Transfusion-Dependent Anemia due to Low- to Intermediate-Risk Myelodysplastic Syndromes (MDS) • Business Wire • 02/23/2024 11:59:00 AM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM